| 1 | Bevacizumab biosimilar LY01008 compared with bevacizumab(Avastin)as first-line treatment for Chinese patients with unresectable,metastatic,or recurrent non-squamous non-small-cell lung cancer:A multicenter,randomized,double-blinded,phase Ⅲ trial显示文摘Background:Previous studies have demonstrated the preclinical pharmacological and toxicological consistency,and clinical pharmacokinetic equivalence of bevacizumab biosimilar LY01008 with reference bevacizumab(Avastin).This randomized controlled trial aimed to compare the efficacy and safety of LY01008 with Avastin in first-line treatment of Chinese patients with advanced or recurrent non-squamous non-small cell lung cancer(NSCLC).Methods:StageⅢB-ⅣNSCLC patients with evaluable lesions,good physical status,and adequate organ functions from 67 centers across China were randomized in a ratio of 1:1 to receive LY01008 or Avastin 15 mg/kg intravenously in combination with paclitaxel/carboplatin(combined treatment)for 4-6 cycles,followed by maintenance monotherapy with LY01008 until disease progression,intolerable toxicity,or death.The primary endpoint was objective response rate(ORR)in accordance with Response Evaluation Criteria in Solid Tumors(RECIST)version 1.1 confirmed by independent radiological review committees(IRRC).Secondary endpoints included disease control rate(DCR),duration of response(DoR),progression-free survival(PFS),overall survival(OS),and safety.This study was registered in Clinical Trials.gov(NCT03533127).Results:Between December 15^(th),2017,and May 15^(th),2019,a total of 649 patients were randomized to the LY01008(n=324)or Avastin(n=325)group.As of September 25th,2019 for primary endpoint analysis,589 patients received ORR evaluation,with a median number of combined treatment cycles of 5(range 1-6)andmedian duration of treatment of 3.0(range 0.0-5.1)months.ORRof responseevaluable patients in the LY01008 and Avastin groups were 48.5% and 53.0%,respectively.The stratified ORR ratio was 0.91(90%CI 0.80-1.04,within the prespecified equivalence margin of 0.75-1.33).Up to May 15^(th),2020,with a median follow-up of 13.6(range 0.8-28.4)months,no notable differences in DCR,median DoR,median PFS,median OS,and 1-year OS rate were observed between the LY01008 and Avastin groups.There were no clinically meaningful differences in safety and immunogenicity across treatment groups.Conclusions:LY01008 demonstrated similarity to Avastin in terms of efficacy and safety in Chinese patients with advanced or recurrent non-squamous NSCLC.LY01008 combined with paclitaxel/carboplatin is expected to become a new treatment option for unresectable,metastatic,LY01008 and Avastin groups.There were no clinically meaningful differences in safety and immunogenicity across treatment groups.Conclusions:LY01008 demonstrated similarity to Avastin in terms of efficacy and safety in Chinese patients with advanced or recurrent non-squamous NSCLC.LY01008 combined with paclitaxel/carboplatin is expected to become a new treatment option for unresectable,metastatic,or recurrent non-squamous NSCLC patients in the first-line setting. | Yuankai Shi Kaijian Lei Yuming Jia Bingqiang Ni Zhiyong He Minghong Bi Xicheng Wang Jianhua Shi Ming Zhou Qian Sun Guolei Wang Dongji Chen Yongqian Shu Lianke Liu Zhongliang Guo Yong Liu Junquan Yang Ke Wang Ke Xiao LinWu Tienan Yi Debin Sun Mafei Kang Tianjiang Ma Yimin Mao Jinsheng Shi Tiegang Tang Yan Wang Puyuan Xing Dongqing Lv Wangjun Liao Zhiguo Luo Bin Wang Xiaohong Wu Xiaoli Zhu Shuhua Han Qisen Guo Rongyu Liu Zhiwei Lu Jianyong Zhang Jian Fang Changlu Hu Yinghua Ji Guolong Liu Hong Lu Dedong Wu Junhong Zhang Shuyang Zhu Zheng Liu Wensheng Qiu Feng Ye Yan Yu Yanqiu Zhao Qinhong Zheng Jun Chen Zhanyu Pan Yiping Zhang Wenjuan Lian Bo Jiang Bo Qiu Guojun Zhang Hua Zhang Yanju Chen Yuan Chen Hongbing Duan Manxiang Li Shengming Liu Lijun Ma Hongming Pan Xia Yuan Xueli Yuan Yulong Zheng Emei Gao Li Zhao Shumin Wang Can Wu | 2021 | Cancer Communications2021，41，9： | 5 |
| 2 | Silver nanocrystals sensitize magnetic-nanoparticle-mediated thermo-induced killing of cancer cells显示文摘磁性的 nanoparticles (MNP ) 能加热肿瘤纸巾起来并且导致在外部交流磁场下面癌症房间杀死。然而,磁性的 nanoparticles 过高热(MNPH ) 要求被注入肿瘤以便因为复杂的热转移,在 vivo 和 MNP 的有限的热质量获得临床上需要的热剂量的 MNP 的高集中。为了切,击倒 MNP 的剂量并且提高这 Nanotherapy 的效果,我们与不同尺寸准备了银 nanoparticles (AgNPs ) 并且在 MNPH 治疗在癌症房间上调查了这些 AgNPs 的效果。AgNPs 能提高 glioma 房间的 thermo 敏感,这效果是尺寸依赖者,这被发现。AgNPs 能导致在 G2/M 阶段逮捕并且在过高热以后提高了癌症房间的 apoptosis 率的房间周期。在适用的老鼠建模的 glioma,与 AgNPs 相结合的 MNPH 能在癌症房间提高 Bax 表示。我们的结果建议 AgNPs 能是潜在的 thermo 敏化并且能进一步为 MNPH 治疗为 Ag 基于 nanostructure 的热种子的设计被开发。 | Lianke Liu Fang Ni Jianchao Zhang Xiaoli Jiang Xiang Lu Zhirui Guo Ruizhi Xu | 2011 | Acta Biochimica et Biophysica Sinica2011，43，4： | 4 |
| 4 | A RELIABILITY ENHANCED DENSITY ADAPTIVE DATA DISSEMINATION SCHEME FOR VANETS显示文摘In this paper,a reliability enhanced and density adaptive data disseminating scheme is proposed for Vehicular Ad hoc NETworks(VANETs).The distributed on demand inquiring and responding mechanism is employed to get nodes' connectivity information.The announcing-listening process is also designed to find the nodes with bigger additional degree to rebroadcast,by which the relaying node is selected freely from density's influence.Simultaneously,a reliability parameter is designed to choose redundant relays for each hop.According to the importance of the broadcast,the parameter is set by the source node properly.Simulation results show that the scheme has achieved good performances such as low forwarding ratio,short latency and low load.The broadcast coverage ratio is ensured against the influence of key link errors and relaying nodes failure by paying suitable additional communication. | Zhou Lianke Cui Gang Luo Danyan Liu Hongwei | 2011 | Journal of Electronics(China)2011，28，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员